Active, not recruitingPHASE1, PHASE2NCT02223208
Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas
Studying ALK-negative anaplastic large cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fondazione Italiana Linfomi - ETS
- Principal Investigator
- Paolo Corradini, ProfFondazione IRCCS Istituto Nazionale dei Tumori di Milano
- Intervention
- Ro-CHOEP-21 (PHASE I)(drug)
- Enrollment
- 89 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2014 – 2026
Study locations (27)
- Ospedale SS. Antonio e Biagio e Cesare Arrigo, Alessandria, AL, Italy
- Policlinico S. Orsola Malpighi, Bologna, BO, Italy
- Spedali Civili, Brescia, BS, Italy
- Ospedale Businco, Cagliari, CA, Italy
- Azienda Ospedaliera S.Croce e Carle, Cuneo, CN, Italy
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) - Sede di Meldola, Meldola, FC, Italy
- IRCCS AOU San Martino - Clinica Ematologica, Genova, GE, Italy
- IRCCS AOU San Martino - UO Ematologia 1, Genova, GE, Italy
- Istituto Clinico Humanitas, Rozzano, Milano, Italy
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, MI, Italy
- Fondazione IRCCS "Istituto Nazionale dei Tumori", Milan, MI, Italy
- Azienda Ospedaliera Ospedale Niguarda Ca' Granda, Milan, MI, Italy
- AO Ospedali Riuniti Villa Sofia - Cervello (Presidio Cervello), Palermo, PA, Italy
- IRCCS Centro di Riferimento Oncologico (CRO), Aviano, PN, Italy
- AOU di Parma, Parma, PR, Italy
- +12 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02223208 on ClinicalTrials.govOther trials for ALK-negative anaplastic large cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07300514Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell LymphomaFudan University
- RECRUITINGPHASE2NCT07356245Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell LymphomaJonathan Brammer
- RECRUITINGPHASE1NCT06176690Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive LymphomasBaylor College of Medicine
- RECRUITINGPHASE1NCT07001384A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)Memorial Sloan Kettering Cancer Center
- ACTIVE NOT RECRUITINGPHASE2NCT07013565Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCLNew York Medical College
- RECRUITINGPHASE2NCT05996185Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell LymphomaYale University
- RECRUITINGPHASE1NCT06508463Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell LymphomaMayo Clinic
- RECRUITINGPHASE1, PHASE2NCT04925609Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid TumorsPrincess Maxima Center for Pediatric Oncology
See all trials for ALK-negative anaplastic large cell lymphoma →